Sanofi Aventis Pakistan Limited reported unaudited earnings results for the first quarter ended March 31, 2012. For the quarter, the company reported net profit of PKR 10,155,000 or PKR 1.05 per basic share on net sales of PKR 1,920,962,000 compared to net loss of PKR 7,200,000 or PKR 0.75 per basic share on net sales of PKR 1,900,934,000 a year ago. Operating profit was PKR 81,837,000 compared to PKR 70,664,000 a year ago. Profit before taxation was PKR 51,913,000 compared to PKR 46,188,000 a year ago. Total comprehensive income was PKR 10,155,000 compared to loss of PKR 7,200,000 a year ago. Net cash generated from operating activities was PKR 94,069,000 compared to PKR 269,386,000 a year ago. Capital expenditures were PKR 26,280,000 compared to PKR 6,739,000 a year ago. The sales growth, despite the challenging business environment, is the result of the company's strategy to become "A diversified health-care company with patient centric approach". Operating income for the period includes gain on sales of scrap and license fee from related party amounting to PKR 2,610,000 and PKR 2,300,000 respectively. Barring unforeseen events, the company expects the sales growth in the remaining quarters of 2012 to be in line with the industry trend. However, due to an adverse impact of Pakistan Rupee depreciation and inflation, overall profitability is an area of concern for the Pharmaceutical industry.